細菌性膣症(Bacterial Vaginosis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Vaginosis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Vaginosis – Overview 7
Pipeline Products for Bacterial Vaginosis – Comparative Analysis 8
Bacterial Vaginosis – Therapeutics under Development by Companies 9
Bacterial Vaginosis – Therapeutics under Investigation by Universities/Institutes 10
Bacterial Vaginosis – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bacterial Vaginosis – Products under Development by Companies 14
Bacterial Vaginosis – Products under Investigation by Universities/Institutes 15
Bacterial Vaginosis – Companies Involved in Therapeutics Development 16
AmVac AG 16
Osel Inc. 17
Starpharma Holdings Limited 18
Valeant Pharmaceuticals International, Inc. 19
Bacterial Vaginosis – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
AMV-100 – Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
astodrimer – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
benzoyl peroxide – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LACTIN-V – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Peptide for Bacterial Vaginosis – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Product-55394 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
secnidazole – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Bacterial Vaginosis – Recent Pipeline Updates 33
Bacterial Vaginosis – Dormant Projects 37
Bacterial Vaginosis – Discontinued Products 38
Bacterial Vaginosis – Product Development Milestones 39
Featured News & Press Releases 39
Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis 39
Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 40
Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis 40
Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis 42
Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis 44
Jun 25, 2012: Starpharma Completes Patient Recruitment For Phase II And First Pivotal Phase III Trials Of VivaGel 44
Jun 04, 2012: Starpharma Completes 60% Patient Recruitment For Phase III Trials Of VivaGel 45
Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis 46
Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment 46
Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49